Physiopathology and management of pain in multiple myeloma;Fisiopatologia e trattamento del dolore nel mieloma multiplo

Minerva Medica

Volumn 101, Issue 6, 2010, Pages 427-438

  Giovannini, M ^a   Scaramucci, L ^a   Tendas, A ^a   Niscola, P ^a  

^a S EUGENIO HOSPITAL   (Italy)

Author keywords

Analgesia; Analgesics, opioid; Drug therapy; Multiple myeloma; Radiotherapy

Indexed keywords

ANALGESIC AGENT;

BONE DISEASE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CHRONIC PAIN; CLINICAL FEATURE; HUMAN; IATROGENIC DISEASE; MULTIPLE MYELOMA; MYELOMA; ORTHOPEDIC SURGERY; OSTEOLYSIS; OSTEOPENIA; PATHOPHYSIOLOGY; PERCUTANEOUS VERTEBROPLASTY; PROGNOSIS; REVIEW; WORLD HEALTH ORGANIZATION;

ANALGESICS; HUMANS; MULTIPLE MYELOMA; PAIN; PAIN MEASUREMENT;

EID: 79952680390     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F et al. Pain syndromes in haematological malignancies: an overview. Hematol J 2004;5:293-303. (Pubitemid 39214206)
2. Poulos AR, Gertz MA, Pankratz VS, Post-White J. Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol Nurs Forum 2001;28:1163-71.
3. Lennert H. Pain therapy in multiple myeloma - clinical experience from an observational study. The pain clinic 2006;18:131-6.
4. Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group;British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-51.
5. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
6. Zappasodi P, Corso A, Klersy C, Pica G, Mangiacavalli S, Varettoni M et al. Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience. Eur J Cancer 2000;42:396-402.
7. Niscola P, Romani C, Cartoni C, Cupelli L, Piccioni D, Dentamaro T et al. Epidemiology of pain in hospital haematological setting: An Italian survey. Leuk Res 2008;32:197-8. (Pubitemid 350100837)
8. Niscola P, Cartoni C, Romani C, Brunetti GA, D'Elia GM, Cupelli L et al. Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Ann Hematol 2007;86:671-6. (Pubitemid 47193597)
9. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-41.
10. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005;18:673-88. (Pubitemid 40984121)
11. Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008;26:55-65. (Pubitemid 351951333)
12. Suzuki M, Ohashi K, Sakamaki H. Immunoglobulin D plasmacytoma carrying aberrant expression of CD33 associated with aggressive visceral involvement. Haematologica 2001;86:895. (Pubitemid 32847464)
13. Niscola P, Scaramucci L, Morabito F, Gomes V, De Gregoris C, Palombi F et al. Pleural effusion by malignant plasma cells in advanced multiple myeloma: report of three cases with a brief overview. Haema 2004;7:516-9. (Pubitemid 39390386)
14. Ochiai N, Shimazaki C, Okano A, Hatsuse M, Takahashi R, Hirai H et al. Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma. Leuk Lymphoma 2002;43:641-3.
15. Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E et al. Infection-an underappreciated cause of bone pain in multiple myeloma. Br J Haematol 2003;120:1047-50. (Pubitemid 36411564)
16. Niscola P, Perrotti AP, del Poeta G, Romani C, Palombi M, Piccioni D et al. Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. Herpes 2007;14:45-7. (Pubitemid 47556310)
17. Coutaux A, Salomon L, Rosenheim M, Baccard AS, Quiertant C, Papy E et at. Care related pain in hospitalized patients: a cross-sectional study. Eur J Pain 2008;12:3-8.
18. Niscola P, Romani C, Cupelli L, Scaramucci L, Tendas A, Dentamaro T et al. Mucositis in patients with hematologic malignancies: an overview. Haematologica 2007;92:222-31.
19. Niscola P, Romani C, Scaramucci L, Dentamaro T, Cupelli L, Tendas A et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant 2008;41:757-64.
20. Smith LC, Bertolotti P, Curran K, Jenkins B; IMF Nurse Leadership Board. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008;12(3 Suppl):37-52.
21. Siniscalchi A, Tendas A, Ales M, Fratoni S, Cupelli L, Dentamaro T et al. Bortezomib-related colon mucositis in a multiple myeloma patient. Support Care Cancer 2009;17:325-7.
22. Srinivasan D, Shetty S, Ashworth D, Grew N, Millar B. Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws. Br Dent J 2007;203:91-2.
23. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008;26:5904-9.
24. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20.
25. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62.
26. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69.
27. Treister NS, Richardson P, Schlossman R, Miller K, Woo SB. Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:e1-4.
28. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14. (Pubitemid 46630990)
29. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008;13:275-82.
30. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1:194-205.
31. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
32. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8:296-306. (Pubitemid 46551871)
33. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20. (Pubitemid 46638949)
34. El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma 2008;8:146-52.
35. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593-9.
36. Ravaglia S, Corso A, Piccolo G, , Lozza A, Alfonsi E, Mangiacavalli S et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008;119:2507-12.
37. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9. (Pubitemid 34132314)
38. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 2003;104:550-8. (Pubitemid 36337254)
39. Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M. Translational medicine: cancer pain mechanisms and management. Br J Anaesth 2008;101:87-94. (Pubitemid 351881906)
40. Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006;35:632-40. (Pubitemid 44194492)
41. Dinter DJ, Neff WK, Klaus J, Böhm C, Hastka J, Weiss C et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol 2009;88:457-64.
42. Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur J Radiol 2009;70:401-8.
43. Cruccu G, Truini A. Tools for assessing neuropathic pain. PLoS Med 2009;6:e1000045.
44. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 2002;23:239-55. (Pubitemid 34219075)
45. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72.
46. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113:1588-95.
47. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-31. (Pubitemid 46335677)
48. Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:1031-5.
49. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8. (Pubitemid 39628580)
50. Tariman JD, Love G, McCullagh E, Sandifer S; IMF Nurse Leadership Board. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008;12(3 Suppl):29-36.
51. Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006;10:279-87. (Pubitemid 44122751)
52. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507-15.
53. Niscola P, Scaramucci L, Romani C, Giovannini M, Maurillo L, del Poeta G et al. Opioids in pain management of blood-related malignancies. Ann Hematol 2006;85:489-501. (Pubitemid 44283092)
54. Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol 2000;176:506-12.
55. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003;15:345-52. (Pubitemid 37069647)
56. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003;95:222-9.
57. Rades D, Hoskin PJ, Stalpers LJ, Schulte R, Poortmans P, Veninga T et at. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 2006;64:1452-7.
58. Munk PL, Rashid F, Heran MK, Papirny M, Liu DM, Malfair D et al. Combined cementoplasty and radiofrequency ablation in the treatment of painful neoplastic lesions of bone. J Vasc Interv Radiol 2009;20:903-11.
59. Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 2007;15:339-42.
60. Abruzzese E, Iuliano F, Trawinska MM, Di Maio M. 153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opin Investig Drugs 2008;17:1379-87.
61. Masala S, Anselmetti GC, Marcia S, Massari F, Manca A, Simonetti G. Percutaneous vertebroplasty in multiple myeloma vertebral involvement. J Spinal Disord Tech 2008;21:344-8.
62. Astolfi S, Scaramuzzo L, Logroscino CA. A minimally invasive surgical treatment possibility of osteolytic vertebral collapse in multiple myeloma. Eur Spine J 2009;18 Suppl 1:115-21.
63. Tran Thang NN, Abdo G, Martin JB, Seium-Neberay Y, Yilmaz H, Verbist MC et al. Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance. Support Care Cancer 2008;16:891-6.
64. No authors listed. World Health Organization. Cancer pain Relief. World Health Organization; Geneva 1986.
65. Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 2009;22:467-74.
66. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003;326:748-50. (Pubitemid 36408042)
67. Cavazzini F. The combination acetominophen/tramadol in hematological daily practice. Minerva Med 2008;99:631-41.
68. Cartoni C, Brunetti GA, Niscola P, Alfieri PL, Delia GM, Foà R. Pain management of bortezomib-induced neuropathy with oral controlled-release oxycodone. Haematologica 2009;94[suppl.2]:49 abs. 0128.
69. Casuccio A, Mercadante S, Fulfaro F. Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother 2009;10:947-53.
70. Stanos SP. Topical agents for the management of musculoskeletal pain. J Pain Symptom Manage 2007;33:342-55. (Pubitemid 46357603)
71. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 2008;59 Suppl 2:117-33.
72. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18(4 Suppl):S3-13.
73. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 2001;84:587-93.
74. Swarm R, Anghelescu DL, Benedetti C, Boston B, Cleeland C, Coyle N et al. National Comprehensive Cancer Network (NCCN). Adult cancer pain. J Natl Compr Canc Netw 2007;5:726-51.
75. Hartmann LC, Zahasky KM, Grendahl DC. Management of cancer pain. Safe, adequate analgesia to improve quality of life. Postgrad Med 2000;107:267-72.
76. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923.
77. Mercadante S. Methadone in cancer pain. Eur J Pain 1997;1:77-83.
78. Kress HG, Von der Laage D, Hoerauf KH, Nolte T, Heiskanen T, Petersen R et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 2008;36:268-79.
79. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008;44:41-54.
80. Pergolizzi JV Jr, Mercadante S, Echaburu AV, Van den Eynden B, Fragoso RM, Mordarski S et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517-28.
81. Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer 2009;17:715-8.
82. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H et al. Expert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.
83. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122(10 Suppl):S22-32.
84. Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 2009;22:467-74.
85. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004;5:2-19. (Pubitemid 38280714)
86. Niscola P, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Massa P et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 2010;11:752-8.
87. Cassileth B, Trevisan C, Gubili J. Complementary therapies for cancer pain. Curr Pain Headache Rep 2007;11:265-9.
88. Jones LW, Courneya KS, Vallance JK, Ladha AB, Mant MJ, Belch AR et al. Understanding the determinants of exercise intentions in multiple myeloma cancer survivors: an application of the theory of planned behavior. Cancer Nurs 2006;29:167-75. (Pubitemid 44309576)
89. Stanos SP, McLean J, Rader L. Physical medicine rehabilitation approach to pain. Med Clin North Am 2007;91:57-95. (Pubitemid 44880057)
90. Niscola P, Scaramucci L, Romani C, Giovannini M, Tendas A, Brunetti G et al. Pain management in multiple myeloma. Expert Rev Anticancer Ther 2010;10:415-25.